Dr. Pauline Howell

Pauline Howell is a clinical researcher specializing in drug-resistant tuberculosis and global infectious diseases. Her work is closely associated with major international collaborations on novel TB regimens, particularly the bedaquiline–pretomanid–linezolid combination, contributing to pivotal studies published in leading medical journals. Her research supports evidence-based advances in shorter, all-oral treatments for highly resistant TB.

Her scholarship spans clinical trials, cohort analyses, and health economic evaluations, with a strong focus on optimizing regimen safety, dosing strategies, and treatment outcomes. Contributions to studies on predictors of relapse, pediatric TB management, and central nervous system TB reflect a commitment to vulnerable populations and complex disease presentations.

In addition, Pauline Howell has engaged in broader infectious disease research, including COVID-19 therapeutics and HIV post-exposure prophylaxis guidelines. Her work demonstrates expertise in translating clinical evidence into policy-relevant guidance, strengthening TB and HIV care in high-burden settings, particularly in Southern Africa.